{"analyses":[{"ciLowerLimit":"55","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"74","groupDescription":"The study was designed to have 82% power for detecting a 50% improvement in survival from a median of 4 years, as observed in SWOG S9321.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"4-yr survival (%)","paramValue":"64","statisticalMethod":"Kaplan and Meier","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".55","upperLimit":".74","value":".64"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"thalidomide/dexamethasone followed by tandem melphalan peripheral blood stem cell transplantation (with cyclophosphamide and filgrastim or sargramostim support) and prednisone/thalidomide maintenance","id":"OG000","title":"Treatment Arm"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"4-7 years","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"proportion surviving at 4 years"}